Oscar Health (OSCR) Cash & Equivalents (2020 - 2026)

Oscar Health (OSCR) has 7 years of Cash & Equivalents data on file, last reported at $4.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 114.85% year-over-year to $4.8 billion; the trailing twelve-month figure through Mar 2026 stood at $4.8 billion (up 114.85% YoY), and the FY2025 full-year result was $2.8 billion, up 81.65% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $4.8 billion, up from $2.8 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $4.8 billion in Q1 2026 and bottomed at $1.2 billion in Q3 2024.
• The 5-year median for Cash & Equivalents is $2.1 billion (2025), against an average of $2.2 billion.
• The widest annual swing landed in 2023, when Cash & Equivalents sank 33.75%; it then jumped 114.85% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $1.6 billion in 2022, then grew by 20.0% to $1.9 billion in 2023, then retreated by 18.35% to $1.5 billion in 2024, then jumped by 81.65% to $2.8 billion in 2025, then soared by 73.21% to $4.8 billion in 2026.
• The last three Cash & Equivalents figures came in at $4.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.

Peer Comparison